ClinicalTrials.gg
RecruitingNCT07857655Updated Oct 5, 2026

Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck Cancers

A Phase 4 interventional study of Electronic Health Record Review and Fentanyl in Head and Neck Carcinoma, Hypopharyngeal Carcinoma and Laryngeal Carcinoma, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by OHSU Knight Cancer Institute · Phase 4, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 86 studies in Hypopharyngeal Neoplasms with a site in United States — 24 open to participants now, 32 under way, 3 of them phase 3. Hypopharyngeal Neoplasms · United States.

Planned enrollment
29th of 69
58 · median 45
Started
2026
with 3 others
Phase 4
3 of 86
1 open now
Primary completion
2029-07
later than 25 of 31 live
Registered
84th of 86
by date

Among the 86 studies in Hypopharyngeal Neoplasms with a site in United States, this one is the 29th largest by planned enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 4, reaches primary completion later than 25 of the 31 other live ones, and was the 84th registered.

Hypopharyngeal Neoplasms

148 studies on the registry are indexed under Hypopharyngeal Neoplasms; 45 are open to participants now.

Browse Hypopharyngeal Neoplasms studies →

Open to participants now

24 of the 86 studies in Hypopharyngeal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Hypopharyngeal Neoplasms studies recruiting now, 23 (61%) set no upper age limit and 8 (21%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Hypopharyngeal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This phase IV trial compares how well methadone plus standard fentanyl given during surgery (intraoperative) works compared to intraoperative standard fentanyl alone in managing pain after surgery (postoperative) among patients with head and neck cancers. For most head and neck cancers, the standard treatment is surgery to remove the cancer followed by surgical reconstruction, which often requires tissue harvested from another part of the body-known as a "free flap tissue transfer". These procedures are highly complex, demand a two-surgeon team, and often take many hours to complete. The combination of multiple operative sites and extent of the surgery contributes to significant postoperative pain. Methadone is not yet used in the head and neck population but has been utilized in other subspecialties like spine and cardiac surgery. The benefits of methadone may include improved pain control in the first 72 hours postoperatively requiring less opioids postoperatively and improvement in overall pain scores. Giving intraoperative methadone plus standard fentanyl may work better than fentanyl alone in managing postoperative pain among patients with head and neck cancers.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess the effectiveness of intraoperative methadone compared to control in reducing the requirements of morphine milliequivalents (MMEs).

SECONDARY OBJECTIVES:

I. To assess the effectiveness of intraoperative methadone compared to control in reducing objective measures of pain, including MMEs, for up to 72 hours postoperatively.

II. To assess how soon after surgery patients require additional opioid administration for those in the methadone group compared to control.

III. To assess whether additional pain management is required less frequently in the methadone group compared to control.

EXPLORATORY OBJECTIVES:

I. To assess if there is an increase in the incidence of post-operative emesis events in the methadone group compared to the control.

II. To assess the effectiveness of intraoperative methadone compared to control on patient's pain scores daily.

III. To assess whether there is a difference in respiratory status between the methadone group compared to the control.

IV. To assess whether higher rates of naloxone administration are required in the methadone group.

V. To assess if pain control impacted acute recovery more effectively in the methadone group compared to control.

VI. Clinical outcomes that are standard of care may be assessed. VII. To assess if there is any impact on pain at \~1 month postoperatively compared to the control group.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive methadone intravenously (IV) at the time of incision during standard of care (SOC) surgery. Patients also receive SOC fentanyl prior to SOC laryngoscopy procedure.

ARM II: Patients receive SOC fentanyl prior to SOC laryngoscopy procedure and surgery.

After completion of study intervention, patients are followed up at 4-6 weeks.

03

Conditions studied

  • Head and Neck Carcinoma
  • Hypopharyngeal Carcinoma
  • Laryngeal Carcinoma
  • Oral Cavity Carcinoma
  • Oropharyngeal Carcinoma
04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18-89
  • Patients with proven head and neck cancer*. Diagnosis will be confirmed by Otolaryngology-Head and Neck Surgery (OTOHNS) team at our center

    • Oral cavity, oropharyngeal, hypopharyngeal, laryngeal
  • Undergoing surgical intervention with ablative and/or reconstructive OTOHNS surgeons for one of the following:

    • Free flap reconstruction (single or double flaps including: radial forearm free flap [RFFF], osteocutaneous radial forearm flap [OCRFF], fibula free flap [FFF], anterolateral thigh [], scapula flap, latissimus, gracilis, rectus sheath, pectoralis)
    • Resections with pedicled flaps (e.g., pectoralis major, latissimus) with an expected case time of > 4 hours

      • Expected time of surgery is found in the surgery request and in our department, the surgeon puts in these orders

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded if they do not consent, are minors, are deemed part of a vulnerable population or lack decision-making capacity
  • Current use of long-acting opioids
  • Pain patients treated with opioids for pathology unrelated to head and neck cancer and/or chronic pain patients, i.e. chronic back pain
  • Positive screening at interview for illicit drug use, not including marijuana

    • Drug screening is not routinely acquired prior to anesthesia per our institution's standard of care and policies. Any suspected abuse or use is guided by clinical evaluation. Patients with evidence of acute intoxication or concern for prior abuse history will be excluded per clinical judgement
  • to methadone (American Society of Addiction Medicine [ASAM] criteria): , severe respiratory depression, paralytic ileus - in which only hypersensitivity is relevant, since individuals undergoing surgery would not present with the latter
  • Currently on CYP therapies noted in the Food and Drug Administration (FDA) methadone pamphlet to have either decreased efficacy of therapy or reduced metabolism of methadone with concurrent use

    • Rifampin, phenytoin, phenobarbital, carbamazepine, voriconazole, abacavir, amprenavir, darunavir+ritonavir, efavirenz, nelfinavir, nevirapine, ritonavir, telaprevir, lopinavir+ritonavir, saquinavir+ritonavir, tipranavir+ritonavir combination, didanosine, stavudine, zidovudine
  • Extensive surgical interventions that require additional assistance from outside services at the time of reconstruction (i.e. hypopharyngeal cancer also requiring esophagectomy)
  • Head and neck cancers with intracranial components (direct, primary tumor extension, disease)
  • (BMI) > 40
  • Sleep apnea with an apnea-hypopnea index > 30 without planned tracheostomy
  • Stage 3b chronic kidney disease or higher (estimated \< 45)
  • /alanine aminotransferase (AST/ALT) greater than two times the
  • Patients with a history of interval (QTc) prolongation > 500 ms
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Arm I (methadone, fentanyl)

    Patients receive methadone IV at the time of incision during SOC surgery. Patients also receive SOC fentanyl prior to SOC laryngoscopy procedure.

    Other: Electronic Health Record Review · Drug: Fentanyl · Device: Laryngoscopy · Drug: Methadone · Procedure: Surgical Procedure · Other: Survey Administration

  • Active comparator
    Arm II (fentanyl)

    Patients receive SOC fentanyl prior to SOC laryngoscopy procedure and surgery.

    Other: Electronic Health Record Review · Drug: Fentanyl · Device: Laryngoscopy · Procedure: Surgical Procedure · Other: Survey Administration

Interventions

  • OtherElectronic Health Record Review

    Ancillary studies

  • Given SOC fentanyl

    Also known as: Abstral, Duragesic

  • DeviceLaryngoscopy

    Undergo SOC laryngoscopy

  • Given IV

  • ProcedureSurgical Procedure

    Undergo SOC surgery

    Also known as: Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Total morphine milligram equivalents (MMEs) administered in the first 24 hours postoperatively

    MMEs will be calculated using the Stanford Opioid Equivalent calculator and data is obtained from the medication administration record (MAR) in epic. Out of room is standard terminology for when the patient leaves the operating room and a required timestamp per standard workflows across all institutions. Two-sided two-sample t-test will be used to compare mean MMEs administered in the first 24 hours between the methadone and control groups. If data is right skewed, log transformation will be performed prior to t-test. If severe violation to normality assumption is detected graphically or by Shapiro-Wilk hypothesis test, Wilcoxon rank-sum test will be performed instead.

    Time frame: From out of room to 24 hours postoperatively

Secondary outcomes

  1. Cumulative MMEs between 24-48 hours postoperatively and 48-72 hours postoperatively

    Will be analyzed as the same approaches as the primary endpoint with two-sided two-sample t-test. If data is right skewed, log transformation will be performed prior to t-test. If severe violation to normality assumption is detected graphically or by Shapiro-Wilk hypothesis test, Wilcoxon rank-sum test will be performed instead.

    Time frame: From 24 hours postoperatively to 72 hours postoperatively

  2. Time to first dose of oral opioid administered & intravenous opioid administered

    Will be assessed using a time-to-event analysis (log-rank test) to compare between the two groups.

    Time frame: From out of room to discharge, an average of 5 days

  3. Acute pain service (APS) consult placement (Yes/No) and outcome of that consult

    Chi-squared test (or Fisher's exact test if any expected count is \< 5) will be used to compare proportion of APS placement between the two groups. Chi-squared test (or Fisher's exact test if any expected count is \< 5) will be used to assess the ambulatory goals comparing the proportion of goals achieved between the two groups on each post-operative day (POD) period. (POD0, POD1 and POD2).

    Time frame: From out of room to discharge, an average of 5 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Jul 2029, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Oct 5, 2026
StartActual
Sep 22, 2026
Primary completionEst.
Jul 29, 2029
CompletionEst.
Jul 29, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07857655
Responsible party
Ryan Hellums (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Oct 5, 2026
Start date
Sep 22, 2026
Primary completion
Jul 29, 2029 (estimated)
Completion
Jul 29, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Ryan N Hellums
principal investigator · OHSU Knight Cancer Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion